Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 2/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15807564 | 0.91 | LMNA (0.41) | ESRRGADRB3GFERPHLPP2PDK2 | |
| SCHEMBL15807550 | 0.89 | KCNH2 (0.40) | ESRRGADRB3SIGMAR1 | |
| SCHEMBL21996922 | 0.88 | ESRRG (0.42) | ESRRGLTB4RLTB4R2PDK2ACHE | |
| SCHEMBL3015417 | 0.86 | ESRRG (0.56) | ESRRGLTB4RLTB4R2PDK2 | |
| SCHEMBL2240309 | 0.86 | PPARA (0.44) | ESRRGLTB4RLTB4R2PDK2HRH3 | |
| SCHEMBL18067949 | 0.86 | ADRB3 (0.46) | ESRRGADRB3SIGMAR1GFERPHLPP2 | |
| SCHEMBL30264506 | 0.86 | LTB4R (0.46) | ESRRGLTB4RLTB4R2PDK2HRH3 | |
| SCHEMBL1129151 | 0.85 | TAAR1 (0.50) | ESRRGSIGMAR1LTB4RLTB4R2PDK2 | |
| SCHEMBL30954590 | 0.85 | AOC3 (0.47) | ESRRG | |
| SCHEMBL22777273 | 0.85 | ESRRG (0.42) | ESRRGLTB4RLTB4R2PDK2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022076662-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| WO-2022012492-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2022-01-20 | — | — | WO | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| US-6395905-B1 | GABA-A ALPHA 5 LIGANDS USEFUL FOR ENHANCING COGNITION: | MERCK SHARP & DOHME LTD. (GB) | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | TIE1, TEK, KDR | ESRRG 1034/4885ADRB3 2052/4885SIGMAR1 2311/4885 |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | ESRRG 1745/4885ADRB3 4649/4885SIGMAR1 4728/4885 |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | ESRRG 3764/4885ADRB3 397/4885SIGMAR1 3623/4885 |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | ABL1, PRKCA, PRKCQ | ESRRG 3271/4885ADRB3 1238/4885SIGMAR1 4023/4885 |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, ABCC1, UGT2B7 | ESRRG 1237/4885ADRB3 846/4885SIGMAR1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.